Group 1 - The core investment philosophy of the fund manager emphasizes "value investment + absolute return," focusing on valuation, cash flow, and fundamental certainty to achieve long-term stable returns [1][14] - The fund adopts a "core + satellite" allocation framework, avoiding trends and focusing on undervalued assets, with a balanced sector allocation to mitigate risks [1][14] - The fund manager has a strong track record, with a total return of 10.71% since taking over the fund, ranking in the top 28.96% among peers [2][23] Group 2 - The fund's asset allocation primarily consists of high-grade credit bonds, with a significant portion (50%-87%) allocated to credit bonds, and a recent increase in interest rate bonds to 21.33% [3][35] - The equity allocation remains below 20%, with an average historical stock position of 13.14%, focusing on large-cap, undervalued, and high-quality stocks [2][40] - The fund's industry allocation is heavily weighted towards electricity and public utilities, maintaining a proportion of 17.84%-28.06% from Q4 2023 to Q2 2025 [2][48] Group 3 - The fund has demonstrated strong performance in controlling drawdowns, with a maximum drawdown of -1.29%, significantly better than the peer average [2][24] - The probability of making a profit after holding the fund for three months is 92.41%, indicating a high success rate for investors [2][29] - The fund manager employs a dynamic stock selection strategy, focusing on large-cap stocks with low valuations and high quality, while maintaining a balanced growth style [2][40]

Investment Rating - The report assigns a "Buy" rating to the company with a target price of 15.40 CNY for the next six months, based on a current price of 12.11 CNY [1]. Core Insights - The report highlights the company's focus on expanding its new energy vehicle (NEV) offerings, alongside its globalization and smart technology initiatives, which are expected to create new growth opportunities [1][8]. Financial Performance Summary - In the first half of 2025, the company achieved a revenue of 72.69 billion CNY, a year-on-year decrease of 5.3%, while the net profit attributable to the parent company was 2.29 billion CNY, down 19.1% year-on-year [6][22]. - The company’s sales volume increased by 1.6% to 1.355 million units, marking the highest level for the same period in eight years [6][22]. - The gross margin improved to 14.6%, up 0.8 percentage points year-on-year, indicating enhanced profitability in core operations [6][22]. Business Analysis - The company’s NEV sales reached 452,000 units in the first half of 2025, representing a 49.1% year-on-year increase, outperforming the industry average [6][22]. - The company plans to launch 35 new smart NEV models over the next three years, establishing a strong product pipeline for long-term growth [6][22]. - The traditional fuel vehicle segment remains stable, with key models maintaining market leadership, while overseas sales grew by 5.1% to 299,000 units in the first half of 2025 [6][22]. Profit Forecast and Investment Recommendations - The report forecasts EPS of 0.77 CNY, 0.95 CNY, and 1.12 CNY for 2025, 2026, and 2027, respectively [6][68]. - Given the anticipated rapid growth in NEV sales and the expansion of overseas markets, the report assigns a 20x PE ratio for 2025, leading to a target price of 15.40 CNY [6][68].

Report Summary 1. Report Industry Investment Rating No industry investment rating is provided in the report. 2. Core Viewpoints - The differences in central bank systems between domestic and overseas are systematic in deposit reserve systems, accounting system frameworks, and financial regulatory mechanisms, reflecting different economic structures, financial market development stages, and policy goals [3][75]. - These differences are rational choices based on each country's economic development stage, financial market structure, legal system tradition, and policy goal priorities. Developed countries tend to adopt market - led institutional arrangements, while emerging market countries focus more on policy execution, risk prevention, and system stability [75]. - In the future, with the further integration of global financial markets and enhanced macro - policy coordination, central banks may learn from each other's experiences while maintaining their own characteristics to optimize monetary policy frameworks and financial regulatory systems [75]. 3. Summary According to the Catalog 3.1海内外存款准备金制度的异同 - **Historical and Current Significance of Deposit Reserve System** - Historically, it was a fundamental tool for quantitative regulation, controlling inflation and preventing bank runs by limiting banks' lending capacity [8]. - Currently, it serves as a tool for structural regulation and liquidity management, with functions such as adjusting liquidity, supporting key areas, performing counter - cyclical regulation, and guiding market expectations [8]. - **Overseas Deposit Reserve System Status** - **Countries with 0% Reserve Requirement**: The US, UK, Australia, and Canada have a 0% legal deposit reserve requirement. Their monetary policy has shifted from quantitative to price - based, with the marginal role of legal reserves significantly reduced [9][13]. - **Japan and South Korea**: They still maintain the legal deposit reserve system, with rates ranging from 0% - 1.3% in Japan and 0% - 7% in South Korea. They keep it as a "base" and operational support for payment and settlement stability and special - period adjustments [19]. - **Domestic Deposit Reserve System Status** - **"Implicit Lower Limit" of 5%**: It reflects the central bank's "psychological bottom line" in the quantitative monetary policy framework. The reserve system has shifted from a "strong constraint" to a "weak constraint" on bank leverage [23]. - **Significance**: It provides a macro - level buffer for the indirect - financing - based financial system, offers policy space for counter - cyclical adjustment, and is suitable for the current monetary policy operation framework [23]. - **Potential Directions**: The system is likely to be retained. A more feasible short - term path is to unify standards before discussing breaking the "implicit lower limit." Introducing inventory cash as a reserve alternative could release liquidity [26]. 3.2海内外央行会计制度的异同 - **Differences in Central Bank Balance Sheet Items** - **Asset Side**: China's central bank's assets are mainly foreign exchange assets and claims on financial institutions, while those of the US, EU, and Japan are more concentrated in bond holdings, due to different money - issuing mechanisms [28]. - **Liability Side**: China includes currency issuance and financial institution deposits in the "Reserve Money" item, and currently has no "reverse repurchase agreement" item. Its main way of base - money injection is through adjusting the deposit reserve ratio [41]. - **Differences in Accounting Element Measurement Attributes** - **China**: It mainly uses historical cost for asset measurement, which helps maintain financial market stability and reduces workload [52]. - **Overseas**: Central banks use various methods such as amortized cost, historical cost, and fair value. The reasons include differences in policy goals, fiscal relationships, profit - distribution mechanisms, and legal systems [57]. 3.3海内外金融监管体系中宏观审慎与微观审慎的差异 - **US Financial Regulatory System** - **Macro - Prudence**: The Financial Stability Oversight Council (FSOC) is the core coordinating body, with the Fed providing stress - test data and other agencies providing relevant risk data [65]. - **Micro - Prudence**: Different agencies are responsible for the micro - prudential supervision of different financial sub - sectors, such as the OCC for national banks and the Fed for bank - holding companies [65]. - **China's Financial Regulatory System** - **Macro - Prudence**: Under the overall coordination of the Central Financial Commission, the People's Bank of China is the core executive department, responsible for most capital - market macro - prudential management outside the on - exchange market, and the China Securities Regulatory Commission is responsible for on - exchange market supervision [68]. - **Micro - Prudence**: Different agencies are responsible for the micro - prudential supervision of different financial sectors, such as the People's Bank of China for specific areas and the National Financial Regulatory Administration for most non - securities financial institutions [68]. - **Similarities and Differences between China and the US** - **Similarities**: Both countries have established higher - level committees for overall management, involve central banks in macro - prudence, and have commonalities in micro - prudential regulatory goals and indicators [73]. - **Differences**: China emphasizes centralized and unified management, with administrative coordination and window guidance in macro - prudence, while the US has a multi - agency, market - oriented, and legalized regulatory system [73]. 3.4结语 The differences in central bank systems between domestic and overseas are profound and diverse, which are rational choices based on different national conditions. In the future, international cooperation in the fields of digital economy, cross - border capital flow, and systemic risk prevention will be crucial for the construction of a more resilient and inclusive global financial system [75].

Domestic Developments - The State Administration of Foreign Exchange announced reforms to enhance cross-border investment and financing, increasing the convenience and limits for such activities[7] - Nine government departments released 19 specific measures to boost service consumption, aiming to direct public finance and market capital towards key infrastructure and emerging industries[9] - From January to August, national public budget revenue reached 148,198 billion yuan, a year-on-year increase of 0.3%, while expenditure grew by 3.1%[11] International Developments - The Federal Reserve lowered interest rates by 25 basis points, aligning with market expectations, marking a total reduction of 125 basis points in the current easing cycle[22] - The ZEW Economic Sentiment Index for the Eurozone rose to 26.1 in September, indicating improved investor confidence in the European economy[18] - U.S. retail sales in August increased by 0.6% month-on-month, surpassing market expectations, with a year-on-year growth of 2.1% after adjusting for CPI[20] Market Trends - Brent crude oil prices increased by 1.70% week-on-week, while iron ore and copper prices rose by 0.33% and 0.80%, respectively[25] - Real estate sales saw a significant week-on-week increase of 10.31%, indicating a rebound in the housing market[30] - The average price of rebar rose by 0.58% week-on-week, while cement prices slightly decreased by 0.05%[30]

Investment Rating - The report maintains a positive outlook on innovative drugs, AI healthcare, and brain-computer interfaces [1]. Core Insights - The report analyzes 362 pharmaceutical listed companies, including those on the Sci-Tech Innovation Board, reporting a total revenue of 1,084.5 billion yuan in H1 2025, a decrease of 2.1% year-on-year. The net profit attributable to shareholders was 103.64 billion yuan, down 1.1%, while the net profit excluding non-recurring items was 88.905 billion yuan, down 9.4% [3][17]. - In H1 2025, 165 companies achieved revenue growth, accounting for 46% of the total, while 165 companies also reported positive net profit growth, also 46% [17]. Summary by Relevant Sections Overall Industry Performance - The pharmaceutical industry faced pressure from policies and macroeconomic conditions, leading to a decline in performance in H1 2025 [19]. - The overall revenue for the industry decreased by 2.1%, with a net profit decline of 1.1% [46]. Subsector Analysis - **Innovative Drugs and Formulations**: Revenue was 194.6 billion yuan (-2.0%), with net profit at 25.8 billion yuan (+1.2%) [5]. - **Medical Devices**: Revenue decreased to 96.8 billion yuan (-5%), with net profit down 16.9% [5]. - **CXO Services**: Revenue increased by 13.8% to 44.85 billion yuan, with net profit rising 64.6% [5]. - **Active Pharmaceutical Ingredients**: Revenue remained stable at 52.88 billion yuan, with net profit increasing by 19.1% [5]. - **Life Sciences**: Revenue was 3.9 billion yuan (-1.8%), with net profit down 3.6% [7]. - **Medical Services**: Revenue grew by 0.9% to 28.3 billion yuan, but net profit fell by 10.2% [7]. - **Blood Products**: Revenue was approximately 11.7 billion yuan (-0.3%), with net profit down 14.4% [7]. - **Retail Pharmacies**: Revenue was 57.8 billion yuan (+0.1%), with net profit up 0.9% [9]. - **Pharmaceutical Distribution**: Revenue increased by 0.9% to 404.57 billion yuan, with net profit rising 12.4% [9]. - **Traditional Chinese Medicine**: Revenue decreased by 4.8% to 173 billion yuan, with net profit slightly up by 0.6% [9]. - **Vaccine Sector**: Revenue plummeted by 58.0% to 10.5 billion yuan, with a net loss of 0.5 billion yuan [11]. Financial Metrics - The overall gross margin for the industry was 32.4%, with a decline in the four expense ratios [46][49]. - The report highlights that the CXO sector showed the highest growth in both revenue and net profit, indicating a strong recovery trajectory [34][37].

Report Industry Investment Rating No relevant content provided. Core Viewpoints - In the context of unchanged risk preferences, deposit "migration" follows a sequence from pure - bond wealth management products and money market funds to bond funds and equity funds. Pure - bond wealth management products are the main recipients of migrated deposits, followed by money market funds. Bond - type funds have a complex attractiveness structure, and equity funds are mostly outside the deposit migration path. As the equity market strengthens, the order of deposit outflow choices and the bank - to - bank liquidity structure change. The effectiveness of quantity - based indicators such as excess reserves decreases, while the risk of short - term shock to inter - bank liquidity increases, but the central bank's attitude towards liquidity is supportive [1][34][44]. Summary According to the Table of Contents 1 Capital Cross - market Rotation and Its Impact on Bond Market Liquidity 1.1 Cost - effectiveness as an Important Consideration for Deposit "Migration" - Due to the continuous decline in deposit interest rates, both household and corporate deposits are migrating. Households are affected by the decline in deposit interest rates, while enterprises are more affected by the ban on manual interest - supplement policies. Insurance products, pure - bond wealth management products, and bond funds have attracted migrated funds due to their yield advantages [12][15][16]. 1.2 Risk Preferences May Disturb the Direction of Deposit "Migration" - When risk preferences are stable, pure - bond wealth management products have the strongest ability to absorb migrated deposits, with a correlation coefficient of 0.87 between the spread of their yields over deposits and the difference between their scale growth rate and deposit growth rate. Money market funds rank second with a correlation of 0.64. Bond - type funds have a complex attractiveness, and equity funds are less involved in deposit migration. As the equity market strengthens, the order of deposit outflow changes, and the bank - to - bank liquidity structure becomes more complex [1][23][34]. 2 Important Matters - In August 2025, CPI was flat month - on - month and decreased by 0.4% year - on - year; PPI was flat month - on - month and decreased by 2.9% year - on - year. In August, M1 growth continued to pick up, and government bonds were the main support for social financing. The central bank will conduct a 6 - month 6000 - billion - yuan buy - out reverse repurchase operation on September 15, 2025 [55][56][59]. 3 Money Market 3.1 Open - market Operations and Fund Interest Rate Trends - From September 8 to 12, 2025, the central bank net - injected 1961 billion yuan through 7 - day reverse repurchase operations. It is expected that 13845 billion yuan of base money will be withdrawn from September 15 to 19. Bank - to - bank liquidity tightened marginally last week, and DR001 first rose and then fell [61][67]. 3.2 Certificate of Deposit Interest Rate Trends and Repurchase Transaction Volume - In the primary market, commercial banks' inter - bank certificates of deposit had a net financing scale of - 4680.1 billion yuan last week. The issuance scale of joint - stock banks was the largest, but they also had a net financing deficit. The issuance interest rate of certificates of deposit increased compared with the previous week. In the secondary market, the yields of certificates of deposit at all tenors increased due to the marginal tightening of the money market [70][74][79]. 4 Bond Market - In the primary market, the main supply of interest - rate bonds last week was still treasury bonds, with a total issuance scale of 5663.7 billion yuan and a net financing scale of 4155.9 billion yuan. The net financing rhythm of local government bonds from January to August was faster than that of treasury bonds. As of September 12, the cumulative net financing scale of special refinancing bonds in 2025 was 1.97 trillion yuan. In the secondary market, the bond market was in a weak mood last week, with the curve becoming steeper. The daily average turnover rate of active bonds increased, and the liquidity premium of 10 - year treasury bonds widened [83][90][95]. 5 Institutional Behavior Tracking - Last week, the 20 - day moving average of the daily trading volume of inter - bank pledged repurchase was 7.31 trillion yuan, and the average leverage trading scale was about 7.49 trillion yuan. In the cash bond market, state - owned banks increased their purchases of treasury bonds with a maturity of less than 5 years, rural commercial banks turned from selling to buying, insurance companies bought long - term treasury bonds and local bonds, while securities firms and funds sold bonds. In July 2025, the leverage ratio of all institutions in the inter - bank market decreased seasonally [111][119][122].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of 8.96 CNY over the next six months, up from the previous rating [1][10]. Core Insights - The company has shown significant performance recovery, with a notable increase in revenue and net profit driven by its pet business and ongoing research and development efforts [1][7]. - The revenue for the first half of 2025 reached 2.793 billion CNY, reflecting a year-on-year growth of 12.63%, while the net profit attributable to the parent company was 82 million CNY, up 30.19% year-on-year [7]. - The company is focusing on large customer development and synergistic services in the animal health sector, which is expected to enhance its profitability [7]. Financial Performance Summary - Revenue projections for 2024A, 2025E, 2026E, and 2027E are 6,017 million CNY, 6,569 million CNY, 7,190 million CNY, and 7,798 million CNY respectively, with growth rates of 11.30%, 9.17%, 9.46%, and 8.46% [2][9]. - The net profit attributable to the parent company is forecasted to be 71 million CNY in 2024A, increasing to 287 million CNY in 2025E, 351 million CNY in 2026E, and 386 million CNY in 2027E, with growth rates of -82.41%, 305.33%, 22.12%, and 9.99% respectively [2][9]. - The company’s earnings per share (EPS) are projected to be 0.07 CNY in 2024A, rising to 0.28 CNY in 2025E, 0.34 CNY in 2026E, and 0.38 CNY in 2027E [2][9]. Business Segment Performance - The pharmaceutical segment reported strong performance with sales revenue of 999 million CNY, while the biological products segment faced a decline in revenue to 450 million CNY due to increased competition [7]. - The feed segment generated revenue of 536 million CNY, indicating stable performance despite some pricing pressures [7]. - The company is actively investing in the pet health product market, with significant advancements in product development and brand promotion [7]. Research and Development - The company invested 60 million CNY in R&D in the first half of 2025, representing a year-on-year increase of 4.73%, with a research expense ratio of 2.14% [7]. - The company is focusing on developing vaccines and pharmaceuticals for pets, with several new products launched during the reporting period [7]. Valuation and Market Position - The company is valued at a PE ratio of 32 times for 2025, which is competitive compared to its peers in the animal health industry, which have an average PE of 31 times [10][11]. - The company’s market capitalization is approximately 7.577 billion CNY, with a total asset value of 8.882 billion CNY [5].

Group 1 - The core idea of the LPPL model is that all systems have a "breaking point," which can be used to predict market bubbles and crashes [7][10][11] - The model is based on the concepts of positive feedback loops and herding behavior, where rising asset prices attract more investors, leading to accelerated price increases [10][11] - The LPPL model uses a polynomial fitting approach to identify periods of accelerated market trends, which can indicate potential market tops [13] Group 2 - The report discusses historical successful predictions of bull and bear market endings using the LPPL model, providing case studies from 2014-2015 and 2006-2007 [21][22][38] - The model's parameters, such as critical time (tc), power-law exponent (α), and angular frequency (ω), are crucial for predicting market behavior and potential breaking points [17][18] - The methodology for applying the LPPL model involves selecting a starting point based on moving averages and continuously updating price data to forecast bubble burst dates [20][24] Group 3 - The report emphasizes the importance of monitoring key indicators like "prediction intervals" and confidence levels to assess the reliability of the LPPL model's forecasts [25][29][36] - The LPPL model's predictions for current market conditions are discussed, indicating that the model has not yet triggered warning thresholds for potential market corrections [39] - The report provides detailed examples of past market behaviors and the corresponding LPPL model predictions, illustrating the model's practical application in real market scenarios [22][24][28]

Investment Rating - The report maintains a positive outlook on the Hong Kong pharmaceutical industry, particularly on innovative drugs, indicating that the sector has entered a profitability phase [1]. Core Insights - The report highlights that the total revenue of 149 Hong Kong-listed pharmaceutical companies reached CNY 896.12 billion in the first half of 2025, reflecting a 1% increase, while net profit attributable to shareholders was CNY 61.99 billion, up 29.7% [3][11]. - The innovative drug sector has shown significant growth, with 36 companies reporting a revenue of CNY 28.5 billion, a 15.8% increase, and a net profit of CNY 1.8 billion, marking a turnaround to profitability [4][12]. - The report emphasizes the importance of differentiated products and strong commercialization capabilities for companies in the innovative drug sector, suggesting that these factors will drive future growth [3][4]. Summary by Sections Overall Performance - The total revenue for the Hong Kong pharmaceutical industry in H1 2025 was CNY 896.12 billion, with a net profit of CNY 61.99 billion, indicating a positive trend in profitability [3][11]. - 57% of the companies reported positive net profit growth, while 50% achieved revenue growth [11][6]. Sector Breakdown - **Innovative Drugs**: Revenue of CNY 28.5 billion (+15.8%), net profit of CNY 1.8 billion, indicating a shift to profitability [4][12]. - **Chemical Preparations**: Revenue of CNY 90.8 billion (-7.1%), net profit of CNY 20.8 billion (+52.9%), suggesting a potential industry turning point [4][5]. - **Medical Devices**: Revenue of CNY 22.2 billion (+3.5%), net profit of CNY 1.9 billion, with varied trends across sub-sectors [4][5]. - **CXO**: Revenue of CNY 49.8 billion (+11.2%), net profit of CNY 12.8 billion (+93.7%), showing strong growth [4][5]. - **Traditional Chinese Medicine**: Revenue of CNY 58.5 billion (-1.8%), net profit of CNY 4.3 billion (-11.5%), indicating challenges in the sector [5][6]. R&D and Expenses - R&D expenses totaled CNY 31.4 billion, down 7.8%, with a decreasing trend in R&D expense ratios [16][24]. - Sales expenses reached CNY 77.7 billion, down 1.5%, and management expenses were CNY 58.7 billion, down 7.3% [16][24]. 18A Companies Performance - The report analyzed 50 Hong Kong 18A pharmaceutical companies, which generated CNY 44.9 billion in revenue, a 31.48% increase, and a net profit of CNY 2.727 billion, marking a significant turnaround with a 128.4% growth [29][34]. - Cash and cash equivalents for these companies reached CNY 84.4 billion, up 26.99% year-on-year [34][35]. International Expansion - The report notes that the international recognition of domestic innovative drugs is increasing, with over 20 licensing out projects totaling over USD 2 billion, indicating a growing trend in global market engagement [35][36].

Report Industry Investment Rating No relevant content provided. Core Viewpoints - Credit - bond ETFs' share significantly rebounded, while convertible - bond ETFs' popularity weakened. The overall share of credit - bond ETFs remained stable, with slight outflows from some. The share of science - innovation bond ETFs generally increased, and their net value continued to rise. The net value of major bond ETFs all increased, with convertible - bond ETFs leading the gain. Among partial bond ETFs, the urban investment bond ETF had the highest cumulative net inflow this week and this month [2][5][8][9][14][16][20][22][25]. Summary by Directory 1.1 各类债券 ETF 份额走势 - As of September 5, 2025, the shares of treasury - bond, policy - financial - bond, local - bond, credit - bond, and convertible - bond ETFs were 675.94 million, 467.14 million, 79.98 million, 3208.58 million, and 5719.55 million respectively, with a total of 10151.19 million for bond - type ETFs. Compared with the closing on August 29, 2025, they changed by 25.72 million, 0.23 million, 0.20 million, 109.92 million, and 36.30 million respectively, and the total change of bond - type ETFs was 172.38 million [2][5]. 1.2 主要债券 ETF 份额及净值走势 - As of September 5, 2025, the shares of selected major bond ETFs (30 - year treasury - bond ETF, policy - financial - bond ETF, 5 - year local - bond ETF, urban investment bond ETF, and convertible - bond ETF) changed by 7.86 million, - 0.42 million, no change, 55.70 million, and 23.40 million respectively compared with the previous week's closing. Their net values increased by 0.02%, 0.08%, 0.13%, 0.07%, and 0.57% respectively [8][9]. 1.3 信用债 ETF 份额及净值走势 - As of September 5, 2025, the overall share of 8 existing credit - bond ETFs remained stable, with slight outflows from the E Fund Corporate Bond ETF and Credit Bond ETF. Their net values continued to increase, with changes ranging from 0.06% to 0.11% compared with the previous week's closing. Last week, the PCF list of credit - bond ETFs re - included 4 bonds. The top three bonds in the product of excess return change and corresponding duration were 24 Yuezu G2, 25 Runzu G2, and 23 Jigao 02; the last three were 25 Dongguan K1, 24 Jiaomei K2, and 24 Jigao 02 [14][16][18]. 1.4 科创债 ETF 份额及净值走势 - As of September 5, 2025, the shares of 10 existing science - innovation bond ETFs generally increased. Their net values continued to rise, with changes ranging from 0.08% to 0.11% compared with the previous week's closing. Last week, the PCF list of science - innovation bond ETFs re - included 7 bonds. The top three bonds in the product of excess return change and corresponding duration were 25 Lvji K1, 25 Beikong K4, and 25 Zhezi K2; the last three were 25 Bingqi K2, 25 Tiegong K1, and 25 Bingqi K1 [20][22][25]. 1.5 部分债券 ETF 净流入情况 - In terms of weekly and monthly cumulative net inflows, the top three bond ETFs were the urban investment bond ETF, short - term financing ETF, and convertible - bond ETF, with net inflows of 79.81 million yuan, 56.20 million yuan, and 31.21 million yuan respectively. In the past 10 trading days, the top three were the convertible - bond ETF (660.10 million yuan), short - term financing ETF (80.82 million yuan), and urban investment bond ETF (79.81 million yuan); in the past 20 trading days, the top three were the convertible - bond ETF (1488.65 million yuan), Shanghai - Stock - Exchange Convertible - Bond ETF (212.33 million yuan), and urban investment bond ETF (116.34 million yuan) [2][28].